These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The use of intravenous H2-receptor antagonists in a tertiary care hospital. Dettmer RM; Riley TH; Byfield F; Green PH Am J Gastroenterol; 1999 Dec; 94(12):3473-7. PubMed ID: 10606306 [TBL] [Abstract][Full Text] [Related]
31. Gastroesophageal reflux and histamine2 antagonists. Bell SG Neonatal Netw; 2003; 22(2):53-7. PubMed ID: 12696725 [No Abstract] [Full Text] [Related]
32. The impact of China's retail drug price control policy on hospital expenditures: a case study in two Shandong hospitals. Meng Q; Cheng G; Silver L; Sun X; Rehnberg C; Tomson G Health Policy Plan; 2005 May; 20(3):185-96. PubMed ID: 15840634 [TBL] [Abstract][Full Text] [Related]
33. Histamine type 2-receptor antagonists and cancer immunotherapy. Smith T Compr Ther; 1990 Jan; 16(1):8-13. PubMed ID: 1967999 [No Abstract] [Full Text] [Related]
34. A vancomycin drug use evaluation and economic analysis in a cancer treatment centre. Dranitsaris G; Pilla NJ; McGreer A Can J Hosp Pharm; 1994 Apr; 47(2):59-64. PubMed ID: 10134128 [TBL] [Abstract][Full Text] [Related]
35. G-CSF (Granulocyte Colony-Stimulating Factor): follow-up and use in a French University hospital. Furet I; Closson V; Madelaine I; Faure P Can J Hosp Pharm; 1995 Apr; 48(2):90-7. PubMed ID: 10142843 [TBL] [Abstract][Full Text] [Related]
36. A cost comparison of Canadian and U.S. hospital pharmacy departments. Weil TP Hosp Pharm; 1994 Jan; 29(1):15-7, 20-3. PubMed ID: 10131492 [TBL] [Abstract][Full Text] [Related]
37. Use of histamine2-antagonists for the treatment of verruca vulgaris. Fit KE; Williams PC Ann Pharmacother; 2007 Jul; 41(7):1222-6. PubMed ID: 17535844 [TBL] [Abstract][Full Text] [Related]
38. Drug usage evaluation: H2-receptor antagonist use in 30 hospitals. Kowalsky SF; Hamilton RA; Figge HL Hosp Formul; 1991 Sep; 26(9):725-6, 732, 734-6 passim. PubMed ID: 10114004 [TBL] [Abstract][Full Text] [Related]
39. Switching the histamine H2 receptor antagonist famotidine to nonprescription status in Canada. An economic evaluation. Tasch RF; Goeree R; Henke CJ; O'Brien BJ Pharmacoeconomics; 1996 Jan; 9(1):61-75. PubMed ID: 10160088 [TBL] [Abstract][Full Text] [Related]
40. Adjusting dosage intervals of intermittent intravenous ranitidine according to creatinine clearance: a cost-minimization analysis. Connelly JF Hosp Pharm; 1994 Nov; 29(11):992, 996-8, 1001. PubMed ID: 10138581 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]